Alzheimers & Dementia

Alzheimer's & Dementia is the peer-reviewed flagship journal of the Alzheimer's Association, launched in 2005 and published by Wiley, covering the full spectrum of dementia research from basic science to clinical trials, with a 2025 Journal Impact Factor of 12.8《阿尔茨海默病与痴呆》（Alzheimer's & Dementia）是（Alzheimer's Association）的旗舰同行评审期刊，2005 年创刊，由（Wiley）出版，涵盖从基础科学到临床试验的痴呆研究全谱系，2025 年影响因子为 12.8。

Scope

• It aims to bridge the knowledge gaps that separate the traditional fields of dementia research该刊旨在弥合痴呆研究各传统领域之间的知识鸿沟。
• It covers the entire spectrum of dementia research from basic science to clinical trials to social and behavioral investigations该刊覆盖痴呆研究的完整谱系，从基础科学、临床试验到社会与行为学研究。
• It provides a forum for the rapid communication of new findings and ideas该刊为新发现与新思想提供快速交流的平台。
• It seeks the optimal translation of research findings into practical applications and interventions该刊致力于把研究成果最优地转化为实际应用与干预措施。
• It aims to increase knowledge across diverse disciplines so as to promote early detection, diagnosis and intervention该刊旨在增进多学科知识，以促进早期检测、诊断与干预。^[1]
• It hosts consensus frameworks such as the NIA-AA Research Framework for a biological definition of Alzheimer's disease该刊刊载了（NIA-AA Research Framework）等共识框架，用于提出阿尔茨海默病的生物学定义。^[2]
• It encourages the submission of interdisciplinary studies, in-depth reviews and commentaries该刊鼓励投稿跨学科研究、深度综述与评论文章。

History

• It was launched in 2005 by the Alzheimer's Association to share knowledge about Alzheimer's science with the global scientific community该刊由（Alzheimer's Association）于 2005 年创办，旨在与全球科学界共享阿尔茨海默病科学知识。
• It was published by Elsevier in its early years and has been published by Wiley since 2020, when the Alzheimer's Association selected Wiley as its publishing partner该刊早年由（Elsevier）出版，2020 年起改由（Wiley）出版，此前（Alzheimer's Association）选定（Wiley）为其出版合作方。
• It was accepted for indexing by MEDLINE in July 2008该刊于 2008 年 7 月被（MEDLINE）收录。
• It is published monthly, and the most recent volume is Volume 22 for 2026该刊按月出版，最近一卷为 2026 年第 22 卷。
• Its Journal Impact Factor fell from 16.655 in 2022 to 11.1 in 2024 and stood at 12.8 in 2025其影响因子由 2022 年的 16.655 降至 2024 年的 11.1，2025 年为 12.8。
• It remains the top-ranked disease-specific journal in clinical neurology该刊始终是临床神经病学领域排名第一的疾病专类期刊。
• On 1 January 2024 it joined the Wiley open access portfolio, and accepted articles are subject to an article publication charge2024 年 1 月 1 日起该刊加入（Wiley）开放获取系列，被接收文章需缴纳文章出版费。

Editors

• The Editor-in-Chief is Donna M. Wilcock, a professor of neurology at the Indiana University School of Medicine and director of the Center for Neurodegenerative Disorders主编为 Donna M. Wilcock，是（Indiana University School of Medicine）的神经学教授，并担任（Center for Neurodegenerative Disorders）主任。
• The Deputy Editor is Lisa L. Barnes, a professor of gerontology and geriatric medicine at Rush University Medical Center in Chicago, who took up the post in 2023副编辑为 Lisa L. Barnes，是芝加哥（Rush University Medical Center）的老年学与老年医学教授，2023 年出任该职。
• Timothy J. Hohman, a professor of neurology at Vanderbilt University Medical Center, serves as a Senior Associate Editor（Vanderbilt University Medical Center）的神经学教授 Timothy J. Hohman 担任高级副编辑。
• Jason Hassenstab, a professor at Washington University in St. Louis, serves as a Section Editor for cognition and digital biomarkers（Washington University in St. Louis）的教授 Jason Hassenstab 担任认知与数字生物标志物方向的栏目编辑。
• The brain health section is led by Yen Ying Lim脑健康栏目由 Yen Ying Lim 主持。